Clearpoint Neuro Inc
CLPT
View Detailed Chart
8.919USD
-0.471-5.01%
Market hours （ET）Quotes delayed by 15 min
9.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.01%
5 Days
-1.23%
1 Month
-29.04%
6 Months
-58.65%
Year to Date
-34.80%
1 Year
-25.49%
View Detailed Chart
TradingKey Stock Score of Clearpoint Neuro Inc
Currency: USD Updated: 2026-03-27Key Insights
Clearpoint Neuro Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 98 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Clearpoint Neuro Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Clearpoint Neuro Inc Highlights
StrengthsRisks
ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.34% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.97M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 36.97M.
Fairly Valued
The company’s latest PE is -10.06, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.91M shares, decreasing 0.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.77M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.61.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
25.000
Target Price
+166.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Clearpoint Neuro Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Clearpoint Neuro Inc Info
ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
Ticker SymbolCLPT
CompanyClearpoint Neuro Inc
CEOBurnett (Joseph Michael)
Websitehttps://www.clearpointneuro.com/
Related Instruments
+0.40%
-2.39%
-1.48%
-3.56%
-2.14%
-1.58%
-1.62%
-3.17%
-1.71%
-0.31%
-9.18%
-2.00%
-1.11%
+0.72%
+1.17%
-2.73%
-0.88%
-0.61%
-0.84%
-1.75%Popular Symbols
247.180
-1.620 (-0.65%)
166.810
-0.710 (-0.42%)
67247.040
+662.990 (+1.00%)
254.790
-18.560 (-6.79%)
2061.150
+61.150 (+3.06%)
360.367
-1.463 (-0.40%)
4531.960
+39.440 (+0.88%)
102.552
+1.943 (+1.93%)
1.146
-0.004 (-0.38%)
159.465
-0.787 (-0.49%)
